Literature DB >> 1617677

Subcellular distribution of the anticancer drug mitoxantrone in human and drug-resistant murine cells analyzed by flow cytometry and confocal microscopy and its relationship to the induction of DNA damage.

P J Smith1, H R Sykes, M E Fox, I J Furlong.   

Abstract

Flow cytometry and laser scanning confocal imaging have been used to analyze the uptake of the anticancer topoisomerase II poison mitoxantrone by intact mammalian cells and the results correlated with the induction of DNA damage. Unlike Adriamycin, mitoxantrone displays only minimal levels of red fluorescence when excited at 514 wavelength. However, using these excitation and emission conditions, flow cytometry could detect low levels of fluorescence in human transformed fibroblasts exposed to high concentrations (5-20 microM) of mitoxantrone for 1 h. Over this dose range whole cell fluorescence was a function of cell size and increased with drug concentration while drug-induced DNA-protein cross-linking showed saturation. Confocal microscopy revealed the time- and dose-dependent appearance of fluorescence, interpreted here as reflecting the disposition of drug molecules, preferentially within the cytoplasm, nuclear membrane, and nucleoli. This pattern contrasted with the intense intranuclear fluorescence observed in Adriamycin-treated human cells. Loss of the nuclear membrane during mitosis resulted in an apparent increase in chromatin-associated fluorescence. Photon counting procedures revealed a predominantly cytoplasmic, possibly lysosomal, location for fluorescence from human cells exposed for 1 h to a low but cytotoxic concentration (0.1 microM, yielding approximately 90% cell kill) of mitoxantrone. At this low concentration, human cells displayed minimal levels of DNA strand cleavage or DNA-protein cross-linking. Murine cells, displaying mitoxantrone resistance as part of the P-glycoprotein-mediated multidrug resistance phenotype, showed specific extinction of mitoxantrone-associated fluorescence from inside nuclei but not from within extranuclear compartments. The study demonstrates the feasibility of high resolution studies on the intracellular distribution of mitoxantrone in intact living cells. We suggest a mechanism by which cytoplasmic sequestration of mitoxantrone may be important in determining the response of normal and multidrug-resistant cells as they attempt to progress through mitosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1617677

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.

Authors:  Shyam K Konda; Ruqaya Maliki; Sean McGrath; Belinda S Parker; Tina Robinson; Alex Spurling; Alison Cheong; Peter Lock; Paul J Pigram; Don R Phillips; Lynne Wallace; Anthony I Day; J Grant Collins; Suzanne M Cutts
Journal:  ACS Med Chem Lett       Date:  2017-04-24       Impact factor: 4.345

2.  Localization and molecular interactions of mitoxantrone within living K562 cells as probed by confocal spectral imaging analysis.

Authors:  A Feofanov; S Sharonov; I Kudelina; F Fleury; I Nabiev
Journal:  Biophys J       Date:  1997-12       Impact factor: 4.033

3.  Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: intracellular accumulation and distribution of monomers, aggregates, naphtoquinoxaline metabolite, and drug-target complexes.

Authors:  A Feofanov; S Sharonov; F Fleury; I Kudelina; I Nabiev
Journal:  Biophys J       Date:  1997-12       Impact factor: 4.033

4.  Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells.

Authors:  Fei Shen; Barbara J Bailey; Shaoyou Chu; Aimee K Bence; Xinjian Xue; Priscilla Erickson; Ahmad R Safa; William T Beck; Leonard C Erickson
Journal:  J Pharmacol Exp Ther       Date:  2009-05-07       Impact factor: 4.030

5.  Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells.

Authors:  M E Fox; P J Smith
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 6.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

7.  Magnetic drug targeting reduces the chemotherapeutic burden on circulating leukocytes.

Authors:  Christina Janko; Stephan Dürr; Luis E Munoz; Stefan Lyer; Ricardo Chaurio; Rainer Tietze; Sarah von Löhneysen; Christine Schorn; Martin Herrmann; Christoph Alexiou
Journal:  Int J Mol Sci       Date:  2013-04-02       Impact factor: 5.923

8.  Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance.

Authors:  Benny Zhitomirsky; Yehuda G Assaraf
Journal:  Oncotarget       Date:  2015-01-20

9.  pH-Responsive Triblock Copolymeric Micelles Decorated with a Cell-Penetrating Peptide Provide Efficient Doxorubicin Delivery.

Authors:  Khen Eng Ng; Mohd Cairul Iqbal Mohd Amin; Haliza Katas; Muhammad Wahab Amjad; Adeel Masood Butt; Prashant Kesharwani; Arun K Iyer
Journal:  Nanoscale Res Lett       Date:  2016-12-05       Impact factor: 4.703

10.  Effects of the potassium-sparing diuretic amiloride on chemotherapy response in canine osteosarcoma cells.

Authors:  Andrew C Poon; Jordon M Inkol; Anita K Luu; Anthony J Mutsaers
Journal:  J Vet Intern Med       Date:  2018-12-17       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.